Structurally-modified Antibody, Immunoglobulin, Or Fragment Thereof (e.g., Chimeric, Humanized, Cdr-grafted, Mutated, Etc.) Patents (Class 424/133.1)
  • Patent number: 10730953
    Abstract: The present disclosure provides novel anti-PD-1 antibodies, compositions including the new antibodies, nucleic acids encoding the antibodies, and methods of making and using the same.
    Type: Grant
    Filed: October 22, 2019
    Date of Patent: August 4, 2020
    Assignee: AbbVie Biotherapeutics Inc.
    Inventors: Daniel E. H. Afar, Fiona A. Harding, Josue Samayoa
  • Patent number: 10730954
    Abstract: Provided herein are mesothelin (MSLN) targeting trispecific proteins comprising a domain binding to CD3, a half-life extension domain, and a domain binding to MSLN. Also provided are pharmaceutical compositions thereof, as well as nucleic acids, recombinant expression vectors and host cells for making such MSLN targeting trispecific proteins. Also disclosed are methods of using the disclosed MSLN targeting trispecific proteins in the prevention, and/or treatment of diseases, conditions and disorders.
    Type: Grant
    Filed: May 11, 2018
    Date of Patent: August 4, 2020
    Assignee: HARPOON THERAPEUTICS, INC.
    Inventors: Holger Wesche, Bryan D. Lemon, Richard J. Austin, Robert B. Dubridge
  • Patent number: 10725037
    Abstract: Methods and composition for the screening and isolation of aglycosylated antibody Fc domain polypeptides. For example, in certain aspects methods for identifying aglycosylated Fc domains that bind to Fc receptors or preferentially bind to particular Fc receptors are described. Furthermore, the invention provides aglycosylated Fc domains that bind to Fc receptors with high affinity. Enhanced methods and media for prokaryotic based interaction screening are also provided.
    Type: Grant
    Filed: December 13, 2013
    Date of Patent: July 28, 2020
    Assignee: Research Development Foundation
    Inventors: George Georgiou, Sang Taek Jung
  • Patent number: 10717994
    Abstract: The invention provides a recombinant polypeptide X—Y for enhancing cell transduction efficiency of a target agent, wherein X is a cell penetrating peptide DPV3, and Y is an Hsp40-J domain. Also provided is a method for enhancing cell transduction efficiency of a target agent, comprising conjugating/attaching said target agent with a recombinant polypeptide X—Y, wherein X is a cell penetrating peptide DPV3, and Y is an Hsp40-J domain. Further provided is a pharmaceutical composition comprising a therapeutic agent, wherein said therapeutic agent is modified by conjugating/attaching with a recombinant polypeptide X—Y, wherein X is a cell penetrating peptide DPV3, and Y is an Hsp40-J domain.
    Type: Grant
    Filed: December 15, 2016
    Date of Patent: July 21, 2020
    Assignee: AGRICULTURAL TECHNOLOGY RESEARCH INSTITUTE
    Inventors: Chin-Kai Chuang, Yu-Hsiu Su, Tzuyin Lin
  • Patent number: 10711062
    Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind one or more epitopes within a CD33 protein, e.g., human CD33 or a mammalian CD33, and have improved and/or enhanced functional characteristics, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
    Type: Grant
    Filed: August 3, 2018
    Date of Patent: July 14, 2020
    Assignee: ALECTOR LLC
    Inventors: Patricia Culp, Helen Lam, Arnon Rosenthal, Seung-Joo Lee, Nels P. Nielson, Robert Pejchal
  • Patent number: 10711056
    Abstract: The invention is a method for reducing the effector functions of a therapeutic neutralizing antibody by administering to the afflicted subject an effective amount of an engineered aglycosylated human monoclonal antibody containing an engineered Fc region, wherein aglycosylation of the Fc region prevents therapeutic antibody-mediated cell activation, inflammation, C1q binding to the antibody and antibody triggered classical pathway activation.
    Type: Grant
    Filed: December 28, 2012
    Date of Patent: July 14, 2020
    Assignee: NOVELMED THERAPEUTICS, INC.
    Inventor: Rekha Bansal
  • Patent number: 10711060
    Abstract: Antibody molecules that specifically bind to LAG-3 are disclosed. The anti-LAG-3 antibody molecules can be used to treat, prevent and/or diagnose cancerous or infectious disorders.
    Type: Grant
    Filed: December 1, 2017
    Date of Patent: July 14, 2020
    Assignees: NOVARTIS AG, Immutep S.A.S.
    Inventors: Frédéric Triebel, Chrystelle Brignone, Walter A. Blattler, Jennifer Marie Mataraza, Catherine Anne Sabatos-Peyton, Hwai Wen Chang, Gerhard Johann Frey
  • Patent number: 10703824
    Abstract: The present disclosure provides antibodies and antigen-binding fragments capable of penetrating cells via an ENT transporter, such as humanized antibodies. The disclosure also provides conjugates comprising the antibodies or antigen-binding fragments and a heterologous agent. The disclosure further provides methods for making and using the antibodies, antigen-binding fragments and conjugates, including humanized antibodies.
    Type: Grant
    Filed: March 4, 2019
    Date of Patent: July 7, 2020
    Assignee: Valerion Therapeutics, LLC
    Inventors: Dustin D. Armstrong, Jeffrey C. Way
  • Patent number: 10703818
    Abstract: Isolated human monoclonal antibodies which bind to and inhibit human CD25, and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced by a hybridoma, a transfectoma or in a nonhuman transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, nonhuman transgenic animals, hybridomas and transfectomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.
    Type: Grant
    Filed: January 31, 2017
    Date of Patent: July 7, 2020
    Assignee: GENMAB A/S
    Inventors: Janine Schuurman, Catharina Emanuele Gerarda Havenith, Paul Parren, Jan G. J. Van De Winkel, Denise Leah Williams, Jørgen Petersen, Ole Baadsgaard
  • Patent number: 10695333
    Abstract: The present invention relates to a pharmaceutical combination comprising LSZ102 and alpelisib; pharmaceutical compositions comprising the same; and methods of using such combinations and compositions in the treatment or prevention of conditions in which degradation of estrogen receptors combined with PI3K inhibition is beneficial in, for example, the treatment of cancers.
    Type: Grant
    Filed: November 29, 2018
    Date of Patent: June 30, 2020
    Assignee: Novartis AG
    Inventors: Tinya Abrams, Larry Alexander Gaither
  • Patent number: 10696745
    Abstract: The present disclosure provides monoclonal antibodies against protein programmed cell death 1 ligand (PD-L1), which can block the binding of PD-L1 to PD-1, and therefore block the inhibitory function of PD-L1 on PD-1 expressing T cells. The antibodies of disclosure provide very potent agents for the treatment of multiple cancers via modulating human immune function.
    Type: Grant
    Filed: June 11, 2015
    Date of Patent: June 30, 2020
    Inventors: Yong Zheng, Jing Li, Zhisheng Chen
  • Patent number: 10696734
    Abstract: Described herein is secretory IgA isolated from the intestinal luminal fluid and intestinal mucosal of animals such as pigs and cows. Also included are methods of isolating secretory IgA. The secretory IgA is useful in food compositions such as animal and human food compositions as well as pharmaceutical compositions to increase growth rate, improve feed efficiency, reduce gastrointestinal inflammation, reduce a risk of gastrointestinal infection in the animal, or a combination thereof.
    Type: Grant
    Filed: August 29, 2016
    Date of Patent: June 30, 2020
    Assignee: WISCONSIN ALUMNI RESEARCG FOUNDATION
    Inventors: Jordan Marshall Sand, Mark Eric Cook
  • Patent number: 10689459
    Abstract: The present invention relates to a pharmaceutical combination which comprises (a) a phosphatidylinositol 3-kinase inhibitor or pharmaceutically acceptable salt thereof, and (b) a Her3 antagonist, for simultaneous, separate or sequential administration for the treatment of breast cancer brain metastases; a method of treating a subject having a breast cancer brain metastases comprising administration of said combination to a subject in need thereof; use of such combination for the treatment of breast cancer brain metastases; and a commercial package comprising such combination.
    Type: Grant
    Filed: December 10, 2015
    Date of Patent: June 23, 2020
    Assignees: Novartis AG, The General Hospital Corporation
    Inventors: Qing Sheng, Rakesh K. Jain, Vasileios Askoxylakis, Gino B. Ferraro, Dai Fukumura, David P. Kodack
  • Patent number: 10688180
    Abstract: Provided are methods for clinical treatment of cancer (e.g., solid tumors or hematological malignancies) using an anti-KIR antibody in combination with an anti-CTLA-4 antibody.
    Type: Grant
    Filed: September 13, 2017
    Date of Patent: June 23, 2020
    Assignees: BRISTOL-MYERS SQUIBB COMPANY, INNATE PHARMA
    Inventors: Robert F. Graziano, Ashok K. Gupta, Su Young Kim, Jon Wigginton, Pascale Andre
  • Patent number: 10689463
    Abstract: Disclosed are a Fuc3S4S substituted oligoglycosaminoglycan with a weight-average molecular weight (Mw) of about 4.5-9 kD, a pharmaceutical composition containing the Fuc3S4S substituted oligoglycosaminoglycan, a preparation method thereof and a use thereof in preparing medicines for preventing and/or treating thrombotic diseases.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: June 23, 2020
    Assignee: JIUZHITANG CO., LTD.
    Inventors: Jinhua Zhao, Jinxing He, Mingyi Wu, Zhiwen Liu, Na Gao, Longyan Zhao, Zi Li, Feng Lu, Li Xu, Chuang Xiao, Lian Yang, Jun Chen, Lutan Zhou, Wenlie Peng, Jikai Liu
  • Patent number: 10690676
    Abstract: This document relates to methods for quantifying antibody therapeutics using mass spectrometry techniques.
    Type: Grant
    Filed: July 29, 2015
    Date of Patent: June 23, 2020
    Assignee: Mayo Roundation for Medical Education and Research
    Inventors: David R. Barnidge, Maria Alice Vieira Willrich, David L. Murray, Melissa R. Snyder
  • Patent number: 10689443
    Abstract: This invention relates to humanized antibodies that selectively bind the 31.1 epitope on the A33 protein differentially expressed in cancers including, lung cancer, ovarian cancer, pancreas cancer, breast cancer, and colon cancer, and diagnostic and therapeutic usages.
    Type: Grant
    Filed: March 23, 2018
    Date of Patent: June 23, 2020
    Assignee: PRECISION BIOLOGICS, INC.
    Inventors: Xue-Ping Wang, Philip M. Arlen
  • Patent number: 10683547
    Abstract: A method relates to epigenetic markers and their diagnostic and predictive value for respiratory allergy. The method can include assaying a test sample from the patient for a DNA hypermethylation or hypomethylation of at least GLI2 region, in which hypermethylation or hypomethylation of the gene region in the test sample indicates or predicts a respiratory allergy in the patient.
    Type: Grant
    Filed: May 27, 2016
    Date of Patent: June 16, 2020
    Assignee: VITO NV
    Inventors: Patrick de Boever, Sabine Langie
  • Patent number: 10675349
    Abstract: The present invention provides humanized monoclonal antibodies, bi-specific antibodies, antibody conjugates, and fusion proteins that bind to the chemokine receptor CCR4. This antibody is derived from CCR4-IgG1 and recognizes the same epitope. This antibody contains either an IgG4 or a stabilized IgG4 in order to improve binding efficiency and reduce in vivo Fab arm exchange. Binding of the antibodies disclosed herein to CCR4 inhibits ligand-mediated activities and is used to treat symptoms of cancer.
    Type: Grant
    Filed: October 6, 2015
    Date of Patent: June 9, 2020
    Assignee: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Wayne A. Marasco, Quan Zhu, De-Kuan Chang
  • Patent number: 10676525
    Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments, etc., that specifically bind a TREM2 protein, e.g., a mammalian TREM2 or human TREM2, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
    Type: Grant
    Filed: August 3, 2018
    Date of Patent: June 9, 2020
    Assignee: ALECTOR LLC
    Inventors: Tina Schwabe, Eric Brown, Philip Kong, Ilaria Tassi, Seung-Joo Lee, Arnon Rosenthal, Robert Pejchal, Nels P. Nielson
  • Patent number: 10669339
    Abstract: The invention relates generally to antibodies that bind programmed death ligand 1 (PDL1), activatable antibodies that specifically bind to PDL1 and methods of making and using these anti-PDL1 antibodies and anti-PDL1 activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Grant
    Filed: May 31, 2019
    Date of Patent: June 2, 2020
    Assignee: CYTOMX THERAPEUTICS, INC.
    Inventors: James William West, Li Mei, Stephen James Moore, Margaret T. L. Nguyen, Daniel Robert Hostetter, Olga Vasiljeva, Jason Gary Sagert, Jonathan Alexander Terrett
  • Patent number: 10669328
    Abstract: A method for increasing the therapeutic efficacy of a human immunoglobulin G class 1 (IgG1) antibody, includes: mutating the human CH1?1 domain from the antibody, to restore the pairing between CH1 and CL domains that is typical of the other IgG subclasses, or by substituting the human CH1?1 domain by the CH1 domain from a human IgG2 (CH1?2), IgG3 (CH1?3) or IgG4 (CH1?4); the antibody obtained by such method, includes a) a light chain including the following amino acid sequences: i) the Light Chain Variable Region (LCVR) specific from an antigen; and ii) a human kappa (?)Constant (CL) domain; and b) a heavy chain including the following amino acid sequences: i) the Heavy Chain Variable Region (HCVR) specific from the antigen; ii) the CH2 and CH3 domains from a human IgG1; and iii) the CH1 domain from a human IgG1, mutated to restore pairing between CHI and CL domains.
    Type: Grant
    Filed: November 11, 2014
    Date of Patent: June 2, 2020
    Assignee: OGD2 PHARMA
    Inventors: Mylene Dorvillius, Jean-Marc Le Doussal, Mickael Terme
  • Patent number: 10669344
    Abstract: The present invention relates to engineered antibodies and other Fc-domain containing molecules with enhanced agonism and effector functions.
    Type: Grant
    Filed: July 28, 2017
    Date of Patent: June 2, 2020
    Assignee: Janssen Biotech, Inc.
    Inventors: Anthony Armstrong, Mark Chiu, Di Zhang
  • Patent number: 10669346
    Abstract: The present invention relates to a humanized IgG1 isotype anti-CD6 antibody (T1h) that binds to the Scavenger receptor cysteine-rich (SRCR) domain 1 (D1) of CD6 present on the surface of thymic epithelial cells, monocytes, activated T cells and a variety of other cells types.
    Type: Grant
    Filed: May 9, 2018
    Date of Patent: June 2, 2020
    Assignees: BIOCON LIMITED, CENTRO DE INMUNOLOGIA MOLECULAR
    Inventors: Ramakrishnan Melarkode, Pradip Nair, Sundaraj David Rajkumar, Kedarnath Nanjund Sastry, Monalisa Chatterji, Laxmi Adhikary, Hema Balasubramanian, Jose Enrique Montero Casimiro, Josefa Lombardero Valladares, Rolando Perez Rodriguez
  • Patent number: 10660890
    Abstract: An HDAC6-specific inhibitor (i.e., a compound of Formula I or II) is shown to reduce the pathogenesis associated with polycystic disease. Administration of an HDAC6-specific inhibitor attenuated many of the symptoms characteristic of polycystic liver disease including cyst formation, cyst growth and cholangiocyte proliferation. Treatment with a HDAC6-specific inhibitor also increased the amount of bile duct acetylated tubulin and ?-catenin phosphorylation and/or acetylation while reducing bile duct ?-catenin synthesis. These results demonstrate that HDAC6 is overexpressed in cystic cholangiocytes and that its pharmacological inhibition reduces cholangiocyte proliferation and cyst growth.
    Type: Grant
    Filed: October 24, 2014
    Date of Patent: May 26, 2020
    Assignee: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT NIH DIVISION OF EXTRAMURAL INVENTIONS AND TECHNOLOGY RESOURCES (DEITR)
    Inventors: Sergio A. Gradilone, Nicholas F. LaRusso
  • Patent number: 10662254
    Abstract: The instant disclosure provides antibody fragments (e.g., Fab and F(ab?)2) having reduced or no reactivity towards pre-existing anti-hinge antibodies (AHA) and compositions comprising such antibody fragments, as well as methods of making and using such antibody fragments and compositions.
    Type: Grant
    Filed: April 30, 2018
    Date of Patent: May 26, 2020
    Assignee: Genentech, Inc.
    Inventors: Yu-Ju G. Meng, Hok Seon Kim, Ingrid Kim, Christoph Spiess
  • Patent number: 10662250
    Abstract: The present invention relates to immunology, biotechnology and medicine, notably to the field of antitumor pharmaceuticals based on monoclonal antibodies, and can be used in medicine for the treatment of oncological diseases. The object of the invention was to create an efficient and safe universal antitumor agent, the production of which effective, quick and easy. This problem is solved by the proposed humanized monoclonal antibody specific to syndecan-1, of the IgG4 isotype, or with IgG3 fragments and amino acid substitutions for the increase the antibody half-life, characterized by a definite combination of the calculated and created by the authors amino acid and nucleotide sequences, which is used as a self-acting substance for the therapy of tumor diseases. Nucleotide sequences additionally contain a fragment coding for a signal secretory sequence at the N-terminus, and are codon-optimized to increase antibody production in mammalian cells.
    Type: Grant
    Filed: July 21, 2016
    Date of Patent: May 26, 2020
    Inventors: Ilya Vladimirovich Dukhovlinov, Anton Iosifovich Orlov, Mark Borisovich Balazovskiy
  • Patent number: 10654932
    Abstract: The disclosure relates to antibody-polymer conjugates comprising one or more anti-Factor D antibody variants, their production and their use in the preparation of compositions and medicaments for treatment of diseases and disorders associated with excessive or uncontrolled complement activation.
    Type: Grant
    Filed: October 27, 2016
    Date of Patent: May 19, 2020
    Assignee: Genentech, Inc.
    Inventors: Philip E. Hass, Robert F. Kelley, Justin M. Scheer, Whitney Shatz, Devin Tesar, Menno van Lookeren Campagne
  • Patent number: 10653792
    Abstract: The invention provides anti-Ly6E antibodies, immunoconjugates and methods of treating cancer using the same.
    Type: Grant
    Filed: June 27, 2017
    Date of Patent: May 19, 2020
    Assignee: Genentech, Inc.
    Inventors: Peter Chang, Chie Sakanaka
  • Patent number: 10647767
    Abstract: Provided are anti-GM-CSF antibodies or fragments thereof including humanized antibodies and fragments. Also provided are uses of the antibodies and fragments for therapeutic, diagnostic and prognostic purposes. Therapeutic uses of the antibodies and fragments, for example include the treatment of inflammatory and autoimmune diseases and disorders.
    Type: Grant
    Filed: September 18, 2017
    Date of Patent: May 12, 2020
    Assignee: I-Mab Biopharma Co., Ltd.
    Inventors: Zhengyi Wang, Lei Fang, Bingshi Guo, Jingwu Zang
  • Patent number: 10646545
    Abstract: The present invention relates to, inter alia, compositions and methods, including chimeric proteins that find use in the treatment of disease, such as immunotherapies for cancer and autoimmunity. In part, the invention provides, in various embodiments, fusions of extracellular domains of transmembrane proteins that can have stimulatory or inhibitory effects.
    Type: Grant
    Filed: June 29, 2018
    Date of Patent: May 12, 2020
    Assignee: Heat Biologics, Inc.
    Inventors: Taylor Schreiber, George Fromm, Suresh De Silva
  • Patent number: 10647768
    Abstract: The present invention relates to Tri-Specific Binding Molecules, which are multi-chain polypeptide molecules that possess three Binding Domains and are thus capable of mediating coordinated binding to three epitopes. The Binding Domains may be selected such that the Tri-Specific Binding Molecules are capable of binding to any three different epitopes. Such epitopes may be epitopes of the same antigen or epitopes of two or three different antigens. In a preferred embodiment, one of such epitopes will be capable of binding to CD3, the second of such epitopes will be capable of binding to CD8, and the third of such epitopes will be capable of binding to an epitope of a Disease-Associated Antigen. The invention also provides a novel ROR1-binding antibody, as well as derivatives thereof and uses for such compositions.
    Type: Grant
    Filed: May 29, 2015
    Date of Patent: May 12, 2020
    Assignee: MACROGENICS, INC.
    Inventors: Leslie S. Johnson, Ling Huang, Gurunadh Reddy Chichili, Kalpana Shah, Chia-Ying Kao Lam, Stephen James Burke, Liqin Liu, Paul A. Moore, Ezio Bonvini, Bhaswati Barat
  • Patent number: 10640767
    Abstract: Methods for the identification of agents the bind to exo-sites of proteins are provided. Agents identified by the methods described herein and pharmaceutical compositions comprising the identified agents are also provided. Methods of using an identified agent for the treatment or prevention of a disease, disorder, or condition are also provided, including methods of treating or preventing a disease associated with reduced, elevated, or ectopic expression or aberrant activity of a protein comprising an exo-site.
    Type: Grant
    Filed: October 31, 2018
    Date of Patent: May 5, 2020
    Assignee: President and Fellows of Harvard College
    Inventors: Juan Pablo Maianti, David R. Liu
  • Patent number: 10638735
    Abstract: The present invention relates to a method for the generation of VH heavy chain-only antibodies in a transgenic non-human mammal. In particular, the present invention relates to a method for the production of a VH heavy chain-only antibody in a transgenic non-human mammal comprising the step of expressing more than one heterologous VH heavy chain locus in that mammal.
    Type: Grant
    Filed: December 8, 2015
    Date of Patent: May 5, 2020
    Assignee: Erasmus University Medical Center
    Inventors: Franklin Gerardus Grosveld, Richard Wilhelm Janssens, Roger Kingdon Craig
  • Patent number: 10640830
    Abstract: The present invention provides methods for selecting a suitable anticancer drug for the treatment of patient with non-small cell lung cancer (NSCLC). The present invention also provides methods for determining drug resistance in NSCLC patients receiving EGFR inhibitor therapy.
    Type: Grant
    Filed: July 29, 2015
    Date of Patent: May 5, 2020
    Assignee: Société des Produits Nestlé S.A.
    Inventors: Sharat Singh, Phillip Kim, Steven Lockton
  • Patent number: 10633438
    Abstract: There is provided inter alia a polypeptide comprising an immunoglobulin chain variable domain which binds to TNF-alpha, wherein the immunoglobulin chain variable domain comprises three complementarity determining regions (CDR1-CDR3) and four framework regions (FR1-FR4), wherein CDR1-CDR3 and FR1-FR4 are as defined in the specification.
    Type: Grant
    Filed: September 22, 2016
    Date of Patent: April 28, 2020
    Assignee: VHsquared Limited
    Inventors: Scott Crowe, Mike West, Kevin Roberts, Tim Carlton, Luana Maggiore, Marion Cubitt, Keith Ray
  • Patent number: 10633650
    Abstract: The invention provides an expression and secretion system, and methods of using the same, for the expression and secretion of one fusion protein in prokaryotic cells and a second fusion protein in eukaryotic cells. Also provided herein are nucleic acid molecules, vectors and host cells comprising such vectors and nucleic acid molecules.
    Type: Grant
    Filed: August 30, 2017
    Date of Patent: April 28, 2020
    Assignee: Genentech, Inc.
    Inventors: Devin Tesar, Xiaocheng Chen, Mark Dennis, Isidro Hotzel
  • Patent number: 10633452
    Abstract: The invention provides modified antibodies directed against GD2 that have diminished complement fixation relative to antibody-dependent, cell-mediated cytotoxicity, which is maintained. The modified antibodies of the invention may be used in the treatment of tumors such as neuroblastoma, glioblastoma, melanoma, small-cell lung carcinoma, B-cell lymphoma, renal carcinoma, retinoblastoma, and other cancers of neuroectodermal origin.
    Type: Grant
    Filed: July 3, 2018
    Date of Patent: April 28, 2020
    Assignee: Merck Patent GmbH
    Inventor: Stephen D. Gillies
  • Patent number: 10633440
    Abstract: The present invention relates to Tri-Specific Binding Molecules, which are multi-chain polypeptide molecules that possess three Binding Domains and are thus capable of mediating coordinated binding to three epitopes. The Tri-Specific Binding Molecule is preferably characterized in possessing binding domains that permit it to immunospecifically bind to: (1) an epitope of a first Cancer Antigen, (2) an epitope of a second Cancer Antigen, and (3) an epitope of a molecule that is expressed on the surface of an immune system effector cell, and are thus capable of localizing an immune system effector cell to a cell that expresses a Cancer Antigen, so as to thereby facilitate the killing of such cancer cell.
    Type: Grant
    Filed: May 29, 2015
    Date of Patent: April 28, 2020
    Assignee: MACROGENICS, INC.
    Inventors: Ezio Bonvini, Paul A. Moore, Jonathan C. Li, Leslie S. Johnson, Kalpana Shah
  • Patent number: 10633443
    Abstract: CD 19×CD3 bi-specific monovalent diabodies, and particularly, CD 19×CD3 bi-specific monovalent Fc diabodies, are capable of simultaneous binding to CD 19 and CD3, and are used in the treatment of hematologic malignancies.
    Type: Grant
    Filed: September 22, 2015
    Date of Patent: April 28, 2020
    Assignee: MacroGenics, Inc.
    Inventors: Leslie S. Johnson, Ezio Bonvini, Chia-Ying Kao Lam, Paul A. Moore, Liqin Liu, Scott Koenig
  • Patent number: 10633433
    Abstract: The invention provides antibodies that specifically bind to transthyretin (TTR). The antibodies can be used for treating or effecting prophylaxis of diseases or disorders associated with TTR accumulation or accumulation of TTR deposits (e.g., TTR amyloidosis). The antibodies can also be used for diagnosing TTR amyloidosis and inhibiting or reducing aggregation of TTR, among other applications.
    Type: Grant
    Filed: July 2, 2016
    Date of Patent: April 28, 2020
    Assignees: PROTHENA BIOSCIENCES LIMITED, UNIVERSITY HEALTH NETWORK
    Inventors: Tarlochan S. Nijjar, Avijit Chakrabartty, Jeffrey N. Higaki
  • Patent number: 10624881
    Abstract: Provided are methods for inducing apoptosis of cells using quinolinol compounds. Combinations of quinolinol compounds can be used in the methods. Combinations of one or more quinolinol compound and one or more inhibitors of cell growth arrest, e.g., Nutlin3a, can also be used in the methods. Also provided are compositions comprising of one or more quinolinol compound and one or more pharmaceutically acceptable carrier. The compositions can comprise one or more quinolinol compound, one or more pharmaceutically acceptable carrier, and one or more inhibitors of cell growth arrest, e.g., Nutlin3a.
    Type: Grant
    Filed: October 12, 2016
    Date of Patent: April 21, 2020
    Assignee: Health Research, Inc.
    Inventor: Xinjiang Wang
  • Patent number: 10626126
    Abstract: There are provided 5,6-dihydro-4H-dithieno[3,2-b:2?,3?-d]azepine derivatives(as defined in the disclosure) which are useful in the treatment of RSV infection and for the prevention of disease associated with RSV infection.
    Type: Grant
    Filed: April 7, 2017
    Date of Patent: April 21, 2020
    Assignee: PULMOCIDE LIMITED
    Inventors: Simon Fraser Hunt, Stuart Thomas Onions, Vladimir Sherbukhin, Euan Alexander Fraser Fordyce, Jennifer Claire Thomas, Peter John Murray, Matthew Stephen Coates, Daniel William Brookes, Kazuhiro Ito, Peter Strong
  • Patent number: 10626179
    Abstract: The present disclosure relates to methods for treating type 1 diabetes (T1D) using a glucagon receptor blocking agent. More specifically, the present disclosure relates to methods for treating T1D using substantially lower doses of insulin supplementation, or even in the absence of insulin supplementation, using antigen binding and antagonizing proteins, e.g., fully human antibodies that specifically bind to and antagonize the function of the human glucagon receptor.
    Type: Grant
    Filed: June 8, 2015
    Date of Patent: April 21, 2020
    Assignee: REMD Biotherapeutics, Inc.
    Inventors: Hai Yan, Jim Shi
  • Patent number: 10626189
    Abstract: Described herein are methods for the efficient production of a heteromultimeric protein, such as a bispecific antibody. Heteromultimeric proteins may be capable of specifically binding to more than one target molecule or different epitopes on a single target molecule. The methods modulate parameters to improve assembly of the heteromultimeric proteins at higher yield and efficiency than otherwise possible. Also described are compositions comprising a hinge-containing polypeptide, such as a half-antibody.
    Type: Grant
    Filed: October 20, 2017
    Date of Patent: April 21, 2020
    Assignee: Genentech, Inc.
    Inventors: Glen Giese, Amy Lim, Josefine Persson, Justin Scheer, Ambrose Williams
  • Patent number: 10617723
    Abstract: The present invention provides, inter alia, methods for treating or ameliorating an effect of a solid tumor present in a human. These methods include administering intratumorally to the human a unit dose of C. novyi, preferably C. novyi NT, colony forming units (CFUs), which contains about 1×103-1×107 CFUs suspended in a pharmaceutically acceptable carrier or solution. Methods for debulking a solid tumor present in a human, methods for ablating a solid tumor present in a human, a method for microscopically precise excision of tumor cells in a human, methods for treating or ameliorating an effect of a solid tumor that has metastasized to one or more sites in a human, unit doses of C. novyi, preferably C. novyi NT, CFUs, and kits for treating or ameliorating an effect of a solid tumor present in a human are also provided.
    Type: Grant
    Filed: March 28, 2014
    Date of Patent: April 14, 2020
    Assignees: BIOMED VALLEY DISCOVERIES, INC., THE JOHNS HOPKINS UNIVERSITY
    Inventors: Saurabh Saha, Shibin Zhou, Bert Vogelstein, Kenneth W. Kinzler
  • Patent number: 10618965
    Abstract: The present invention demonstrated that the modification of the Fc region of an antigen-binding molecule into an Fc region that does not form in a neutral pH range a heterotetramer complex containing two molecules of FcRn and an active Fc? receptor improved the pharmacokinetics of the antigen-binding molecule and reduced the immune response to the antigen-binding molecule. The present invention also revealed methods for producing antigen-binding molecules having the properties described above, and successfully demonstrated that pharmaceutical compositions containing as an active ingredient such an antigen-binding molecule or an antigen-binding molecule produced by a production method of the present invention have excellent features over conventional antigen-binding molecules in that when administered, they exhibit improved pharmacokinetics and reduced in vivo immune response.
    Type: Grant
    Filed: March 30, 2012
    Date of Patent: April 14, 2020
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Tomoyuki Igawa, Atsuhiko Maeda, Kenta Haraya, Yuki Iwayanagi, Tatsuhiko Tachibana, Futa Mimoto, Taichi Kuramochi, Hitoshi Katada, Shojiro Kadono
  • Patent number: 10618953
    Abstract: The present invention relates to antigen-binding fragment (Fab) and a Fab-effector fusion protein or polypeptide comprising thereof. The Fab of the present invention specifically binds to serum albumin and thereby has extended in vivo half-life. The Fab of the present invention is characterized by not having cysteine residues that are responsible for the interchain disulfide bond in CH1 domain and C kappa L domain as well. The Fab-effector fusion protein or polypeptide of the present invention can be produced in periplasm of E. coli with high yield, and has increased in vivo half-life. Further, the present invention provides E. coli strain which produces various kinds of Fab-effector fusion proteins or polypeptides, and a pharmaceutical composition comprising the fab-effector fusion proteins or polypeptides.
    Type: Grant
    Filed: September 27, 2017
    Date of Patent: April 14, 2020
    Assignee: AprilBio Co., Ltd.
    Inventor: Sanghoon Cha
  • Patent number: 10620208
    Abstract: The present invention relates to a carbonic anhydrase IX targeting compound for the use in the treatment of cancer, wherein the use comprises quantifying CAIX expression as well as the determination of a CAIX score based on the CAIX expression. The present invention relates further to a method for diagnosing, predicting and/or classifying a cancer disease comprising quantifying CAIX expression, and the determination of a CAIX score.
    Type: Grant
    Filed: February 21, 2014
    Date of Patent: April 14, 2020
    Assignee: Wilex AG
    Inventors: Olaf Wilhelm, Paul Bevan, Barbara Fall, Pia Klöpfer
  • Patent number: 10611817
    Abstract: The present invention addresses the first problem of providing an Fc-binding protein having improved stability, especially stability to heat and acid, of the Fc-binding protein, a method for producing this protein, and an antibody adsorbent using this protein. The present invention also addresses the second problem of providing a method that makes it possible to identify the presence or absence of glycosylation of an antibody, and a material to be used in this method. The first problem is solved by an Fc-binding protein having improved stability to heat and acid obtained by substituting amino acid residues at specific positions in the extracellular domain within human Fc?RIIIa with other specific amino acids, a method for producing this protein, and an antibody adsorbent using this protein. The second problem is solved by using an adsorbent capable of specifically adsorbing an antibody having a sugar chain, the adsorbent being obtained by immobilizing human Fc?RIIIa on an insoluble carrier.
    Type: Grant
    Filed: September 18, 2014
    Date of Patent: April 7, 2020
    Assignee: TOSOH CORPORATION
    Inventors: Yoshiharu Asaoka, Toru Tanaka, Teruhiko Ide